Special Issue "Diagnostic Biomarkers in Prostate Cancer"
Deadline for manuscript submissions: closed (14 December 2018)
Prof. Dr. Jochen Neuhaus
Department of Urology, Research Laboratory, University of Leipzig, Leipzig, Germany
Website | E-Mail
Interests: improving the diagnosis of prostate cancer, bladder cancer and other urologic diseases by development of biomarkers; proteomics; NMR-metabolomics; understanding of molecular mechanisms of receptor signaling and trafficking; elucidating the role of the tumor microenvironment; improvement of minimal invasive focal therapies and immune response priming in urologic cancers
Prostate cancer (PCa) is the second most common cancer in men, worldwide, ranking first in more-developed regions and second (behind lung cancer) in less-developed regions. There are considerable variations in incidence and mortality rates in different countries and populations. Despite all efforts, mortality is still high and about one patient in 39 will die of PCa. Detection of PCa and clinical decision making mostly relies on clinical examination and PSA-levels, followed by invasive biopsy where indicated. However, known limitations of PSA diagnostics and the health risks of biopsy taking require more reliable biomarkers to diagnose PCa in first place, stratify for indolent and aggressive tumors in second place and finally allowing non-invasive monitoring of disease development and treatment effects.
This special issue aims to comprehensively cover all aspects of novel PCa biomarker development and validation with special emphasis on new approaches and adaptation of biomarkers to population peculiarities. We also invite manuscripts elucidating the molecular background of biomarkers. Original work, as well as reviews, are welcome.
Thank you for your consideration.
Prof. Dr. Jochen Neuhaus
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 850 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- prostate cancer biomarkers
- diagnostic, stratification and monitoring